Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 6, 2003, Pages 685-694

  Frantz, Stefan ^a,e   Ducharme, Anique ^a,f   Sawyer, Douglas ^b   Rohde, Luis E ^a,g   Kobzik, Lester ^c   Fukazawa, Ryuji ^a   Tracey, Daniel ^d   Allen, Hamish ^d   Lee, Richard T ^a   Kelly, Ralph A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d ABBOTT LABORATORIES   (United States)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f MONTREAL HEART INSTITUTE   (Canada)

^g HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Apoptosis; Cytokines; Heart failure; Infarction; Remodeling

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CYTOKINE PRODUCTION; ENZYME ACTIVITY; EVALUATION; GENE DELETION; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; IMAGING; IMMUNOBLOTTING; KNOCKOUT MOUSE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MORTALITY; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; WILD TYPE;

ANIMALIA;

EID: 12444309815     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00113-5     Document Type: Article

References (41)

1. Kostura M.J., Tocci M.J., Limjuco G., Chin J., Cameron P., Hillman A.G., et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci USA. 86:1989;5227-5231.
2. Ghayur T., Banerjee S., Hugunin M., Butler D., Herzog L., Carter A., et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 386:1997;619-623.
3. Dinarello C.A., Novick D., Puren A.J., Fantuzzi G., Shapiro L., Muhl H., et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 63:1998;658-664.
4. Miura M., Zhu H., Rotello R., Hartwieg E.A., Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell. 75:1993;653-660.
5. Dimmeler S., Haendeler J., Nehls M., Zeiher A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp M. 185:1997;601-607.
6. Li P., Allen H., Banerjee S., Franklin S., Herzog L., Johnston C., et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. 80:1995;401-411.
7. Kuida K., Lippke J.A., Ku G., Harding M.W., Livingston D.J., Su M.S., et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 267:1995;2000-2003.
8. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 81:1997;627-635.
9. Isoda K., Kamezawa Y., Tada N., Sato M., Ohsuzu F. Myocardial hypertrophy in transgenic mice overexpressing human interleukin lalpha. J Card Fail. 7:2001;355-364.
10. Schielke G.P., Yang G.Y., Shivers B.D., Betz A.L. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab. 18:1998;180-185.
11. Melnikov V.Y., Ecder T., Fantuzzi G., Siegmund B., Lucia M.S., Dinarello C.A., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest. 107:2001;1145-1152.
12. Pomerantz B.J., Reznikov L.L., Harken A.H., Dinarello C.A. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA. 98:2001;2871-2876.
13. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:1999;3063-3070.
14. Kajstura J., Zhang X., Reiss K., Szoke E., Li P., Lagrasta C., et al. Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing-induced cardiomyopathy in rats. Circ Res. 74:1994;383-400.
15. Frantz S., Kobzik L., Kim Y.D., Fukazawa R., Medzhitov R., Lee R.T., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 104:1999;271-280.
16. Coker M.L., Thomas C.V., Clair M.J., Hendrick J.W., Krombach R.S., Galis Z.S., et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 274:1998;H1516-H1523.
17. Walsh B.J., Thornton S.C., Penny R., Breit S.N. Microplate reader-based quantitation of collagens. Anal Biochem. 203:1992;187-190.
18. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metallaproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 106:2000;55-62.
19. Sam F., Sawyer D.B., Xie Z., Chang D.L., Ngoy S., Brenner D.A., et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res. 89:2001;351-356.
20. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 53:2002;31-47.
21. Gidron Y., Gilutz .H, Berger .R, Huleihel M. Molecular and cellular interface between behavior and acute coronary syndromes. Cardiovasc Res. 56:2002;15-21.
22. Yaoita H., Ogawa K., Maehara K., Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor (see comments). Circulation. 97:1998;276-281.
23. Anversa P., Leri .A, Beltrami C.A., Guerra S., Kajstura J. Myocyte death and growth in the failing heart. Lab Invest. 78:1998;767-786.
24. Haunstetter A., Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;1111-1129.
25. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1990;1161-1172.
26. Solomon S.D., Greaves S.C., Rayan M., Finn P., Pfeffer M.A., Pfeffer J.M. Temporal dissociation of left ventricular function and remodeling following experimental myocardial infarction in rats. J Card Fail. 5:1999;213-223.
27. Rabuffetti M., Sciorati C., Tarozzo G., Clementi E., Manfredi A.A., Beltramo M. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci. 20:2000;4398-4404.
28. Hosenpud J., Campbell S., Mendelson D. Inerleukin 1 induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 8:1989;460-464.
29. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 98:1998;149-156.
30. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al. Interleukin-18 is a strong predictor of cardiovascular death in stabel and unstable angina. Circulation. 106:2002;24-30.
31. Kelly R.A., Balligand J.L., Smith T.W. Nitric oxide and cardiac function. Circ Res. 79:1996;363-380.
32. Mann D.L., Spinale F.G. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation. 98:1998;1699-1702.
33. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J. III, Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 97:1998;1708-1715.
34. Spinale F.G., Coker M.L., Krombach S.R., Mukherjee R., Hallak H., Houck W.V., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 85:1999;364-376.
35. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 378:1997;151-160.
36. Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 376:1995;345-355.
37. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA. 97:2000;12746-12751.
38. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 90:2002;520-530.
39. Olivetti G., Quaini F., Sala R., Lagrasta C., Corradi D., Bonacina E., et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol. 28:1996;2005-2016.
40. Baldi A., Abbate A., Bussani R., Patti G., Melfi R., Angelini A., et al. Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol. 34:2002;165-174.
41. Kocher A.A., Schuster M.D., Szabolcs M.J., Takuma S., Burkhoff D., Wang J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat M. 7:2001;430-436.